Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Assets (2016 - 2025)

Historic Assets for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $568.7 million.

  • Adma Biologics' Assets rose 4558.65% to $568.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $568.7 million, marking a year-over-year increase of 4558.65%. This contributed to the annual value of $488.7 million for FY2024, which is 4845.22% up from last year.
  • As of Q3 2025, Adma Biologics' Assets stood at $568.7 million, which was up 4558.65% from $558.4 million recorded in Q2 2025.
  • Adma Biologics' 5-year Assets high stood at $568.7 million for Q3 2025, and its period low was $232.8 million during Q2 2021.
  • Its 5-year average for Assets is $360.2 million, with a median of $343.0 million in 2023.
  • Its Assets has fluctuated over the past 5 years, first plummeted by 553.26% in 2023, then skyrocketed by 4845.22% in 2024.
  • Adma Biologics' Assets (Quarter) stood at $276.3 million in 2021, then increased by 26.14% to $348.5 million in 2022, then fell by 5.53% to $329.2 million in 2023, then soared by 48.45% to $488.7 million in 2024, then rose by 16.37% to $568.7 million in 2025.
  • Its Assets stands at $568.7 million for Q3 2025, versus $558.4 million for Q2 2025 and $510.6 million for Q1 2025.